Fabrice Lejeune | CSO
Genvade Therapeutics

Dr. Fabrice Lejeune is the Scientific Advisor & co-Founder of Genvade Therapeutics. He is the author and inventor of the patents for the lead candidate GV-01 and the drug screening platform. He has been a scientific leader in the search for nonsense mutation correctors for over 20 years. He is the lead inventor on four patents relating to NMD inhibitors and/or readthrough activators, with publications in high-impact journals, including Nature Communications and Molecular Therapy. FL has co-founded Genvade Therapeutics as a shareholder and scientific director and will be responsible for the scientific aspects of the company’s drug discovery and develop program.

Appearances:

Day 1 - Tuesday 28 October @ 13:00

Start-ups Pitches

13:00: Dr Mona Boyé, CBDO, Ksilink: Automation and high throughput phenotypic screening of patient-based cellular systems for novel treatment options for rare diseases

13:05: Dr Boris Sevarika, Co-Founder & CEO, NanoZymeX

13:10: Dr William Jang, Head of Global BD, BioMe

13:15: Dr Sumira Riaz, Founder & Health Psychologist, Unboxed Psychology: Applications of behaviour science: Introducing Unboxed Psychology

13:20: Leonid Stoianov, CEO, Trialize

13:25: Julian Howell, M.D., Founder & CEO, PharmaKrysto: Cystinuria – new approaches to preventing cystine stones – moving to clinical development

13:30: Fabrice Lejeune, CSO, Genvade Therapeutics

13:35: Dr Alistair Irvine, CEO, Scarlet Therapeutics

13:40: TBC, ORPHANET-AISBL

Mona Boyé, CBDO, Ksilink

Sumira Riaz, Founder, Health Psychologist & Patient Engagement Consultant, Unboxed Psychology